Back to Search
Start Over
Mammaprint™: A comprehensive review
- Source :
- Future oncology, 15 (2
- Publication Year :
- 2019
-
Abstract
- The number of breast cancer (BC) cases is growing worldwide, being most frequently diagnosed in the early-setting. Mammaprint™ is a 70-gene-expression signature, originally designed for selecting early BC patients with low risk of developing metastasis, so that they could be spared adjuvant chemotherapy. Its use as a prognostic biomarker has been extensively validated, both retrospectively and prospectively. However, its value as a predictive tool and as a clinically useful tool remains controversial. This review will describe how the test works, its application in the clinic and its limitations. Cost-effectiveness studies will be summarized. Finally, we will provide a perspective on the use of Mammaprint in the near future, as a valuable tool for personalizing the treatment of early BC patients.<br />SCOPUS: re.j<br />DecretOANoAutActif<br />info:eu-repo/semantics/published
Details
- Database :
- OAIster
- Journal :
- Future oncology, 15 (2
- Notes :
- No full-text files, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1264150457
- Document Type :
- Electronic Resource